Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up
Brachytherapy · 2024
DOI: 10.1016/j.brachy.2024.01.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2024. Verfasst von Juliette Jacques und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, Institut de Cancérologie de Lorraine, Vandoeuvre-lès- Nancy, France; Université de Lorraine, Faculté de Médecine de Nancy…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Prostate-Specific Antigen, Adenocarcinoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Brachytherapy (BT) is a standard treatment for low- and favorable intermediate-risk prostate adenocarcinoma. Few studies have focused on young patients. We therefore evaluated long-term efficacy and toxicity of BT in patients aged ≤ 60 years with low- and favorable intermediate-risk prostate cancer. MATERIALS AND METHODS: This retrospective study included patients aged ≤60 years with low- or favorable intermediate-risk prostate adenocarcinoma treated with iodine BT alone between 1999 and 2014 at the Institut de Cancérologie de Lorraine. Follow-up assessment included incidence of biochemical failure (BF) at 10 and 15 years after BT, as well as survival data and late toxicities. RESULTS: A total of 177 patients of median age 56 years (54-58) were analyzed, with a median follow-up of 126 months (97-172). Incidence of BF at 10 and 15 years after BT was 5.4% and 11.7% respectively. PSA nadir (HR = 51.8 [95% CI 6.69-277], p < 0.001), age at treatment (HR = 1.78 [95% CI 1.19-2.65], p = 0.005) and prostate D90% (HR = 1.08 [95% CI 1.01-1.15], p < 0.021) were identified as predictive factors of BF. Overall survival at 10 and 15 years after BT was 92.8% and 84.4% respectively. Cancer-specific survival at 10 and 15 years after BT was 99.3% and 97.7% respectively. No major toxicity was recorded. CONCLUSIONS: Exclusive BT is a long-term effective treatment for patients aged ≤ 60 years with low- or favorable intermediate-risk prostate adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiotherapy, Institut de Cancérologie de Lorraine, Vandoeuvre-lès- Nancy, France; Université de Lorraine, Faculté de Médecine de Nancy, Vandoeuvre-lès-Nancy, France. Electronic address: j.jacques@nancy.un…
- Methodology Biostatistic unit, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.
- Department of Radiotherapy, Institut de Cancérologie de Lorraine, Vandoeuvre-lès- Nancy, France.
- Department of Radiotherapy, Institut de Cancérologie de Lorraine, Vandoeuvre-lès- Nancy, France; Université de Lorraine, Faculté de Médecine de Nancy, Vandoeuvre-lès-Nancy, France.
- Department of Radiotherapy, Institut de Cancérologie de Lorraine, Vandoeuvre-lès- Nancy, France; Université de Lorraine, Faculté de Médecine de Nancy, Vandoeuvre-lès-Nancy, France; APEMAC, Université de Lorraine, Facult…
Zitieren
APA
Jacques, J., Sahki, N., Meknaci, É., Eschwege, P., Peiffert, D., & Demogeot, N. (2024). Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up. Brachytherapy. https://doi.org/10.1016/j.brachy.2024.01.010
Vancouver
Jacques J, Sahki N, Meknaci É, Eschwege P, Peiffert D, Demogeot N. Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up. Brachytherapy. 2024. doi:10.1016/j.brachy.2024.01.010
BibTeX
@article{Jacques2024,
author = {Jacques, Juliette and Sahki, Nassim and Meknaci, Émilie and Eschwege, Pascal and Peiffert, Didier and Demogeot, Nicolas},
title = {Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up},
journal = {Brachytherapy},
year = {2024},
doi = {10.1016/j.brachy.2024.01.010}
}
EUVIMED